Search - tctmd.com

Displaying 21 - 40 of 42

Sort: Relevancy | Date

Inclisiran Approved in Europe for Lowering LDL Cholesterol

News Daily News

Inclisiran Approved in Europe for Lowering LDL Cholesterol

Michael O'Riordan

December 11, 2020

FDA Grants Stroke Prevention Indication to Ticagrelor

News Daily News

FDA Grants Stroke Prevention Indication to Ticagrelor

November 06, 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

News Conference News EAS 2020

Inclisiran Effective Across FH Genotypes, as Well as in Primary Prevention

Michael O'Riordan

October 08, 2020

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

News Daily News

FDA Extends Ticagrelor Indication to High-Risk CAD Primary Prevention

June 01, 2020

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

News Daily News

Most Secondary Prevention Patients Are Eligible for Multiple Drugs

Michael O'Riordan

January 03, 2020

News Daily News

FDA Approves Two Generic Versions of Apixaban

December 23, 2019

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

News Daily News

FDA Advisors Recommend CVD Event Reduction Claim for Icosapent Ethyl

Michael O'Riordan

November 14, 2019

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

News Daily News

Dapagliflozin Gets Expanded Indication for Prevention of HF Hospitalization in Type 2 Diabetes

October 21, 2019

FDA Gives Rivaroxaban Another VTE-Related Indication

News Daily News

FDA Gives Rivaroxaban Another VTE-Related Indication

October 14, 2019

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

News Daily News

PCSK9 Inhibitor Alirocumab Receives Expanded Indication for CV Event Reduction

Michael O'Riordan

April 29, 2019

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

News Daily News

European Regulators Strike Secondary Prevention Claim for Omega-3 Drugs

December 18, 2018

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

News Daily News

FDA Puts the Kibosh on Canakinumab for Cardiac Indication—at Least for Now

Michael O'Riordan

November 01, 2018

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

News Daily News

FDA Approves Rivaroxaban for CV Event Reduction in CAD and PAD Patients

October 12, 2018

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

News Daily News

‘The Bleeding Edge’ Documentary, Tackling Medical Device Regulation, Spurs Diverse Cardiology Reactions

Yael L. Maxwell

August 17, 2018

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

News Daily News

Andexanet Alfa, First Reversal Agent for Factor Xa Inhibitors, Finally Gains FDA Approval

May 04, 2018

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

News Daily News

Year in Review: Physicians Pick the Biggest News of 2017, in Interventional Cardiology and Beyond

December 26, 2017

News Daily News

Betrixaban Approved for Prevention of VTE

Michael O'Riordan

June 23, 2017

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

News Daily News

FDA Approves Amplatzer PFO Occluder for Prevention of Recurrent Stroke

Yael L. Maxwell

October 28, 2016

News Daily News

Un Panel Asesor de la FDA Recomienda por un Estrecho Margen una Indicación de Mortalidad por EAC para el Antidiabético Empagliflozina

Michael O'Riordan

June 30, 2016

News Daily News

FDA 顾问小组小范围建议使用糖尿病药物 empagliflozin 来改善 CVD 死亡率

Michael O'Riordan

June 30, 2016

Country

First Name

Last Name

Email

Profession

Organization

Country

CAPTCHA

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.